Abstract：
In 1987, Won invented the solid-phase porous microsphere (MS), which stores bioactive compounds in many interconnected voids. Spherical particles (5-300 μm), MS, may form clusters of smaller spheres, resulting in many benefits. The current investigation focussed on gel-encased formulation, which can be suitable for dermal usage. First, quasi-emulsion (w/o/w) solvent evaporation was used to prepare 5-fluorouracil (5 FU) MS particles. The final product was characterized (SEM shows porous structure, FTIR and DSC showed drug compatibility with excipients, and gel formulation is shear-thinning) and further scaled up using the 8-fold method. Furthermore, CCD (Central Composite Design) was implemented to obtain the optimized results. After optimizing the conditions, including the polymer (600 mg, ethyl cellulose (EC), eudragit RS 100 (ERS)), stirring speed (1197 rpm), and surfactant concentration (2% w/v), we achieved the following results: optimal yield (63%), mean particle size (152 µm), drug entrapment efficiency (76%), and cumulative drug release (74.24% within 8 h). These findings are promising for industrial applications and align with the objectives outlined in UN Sustainable Development Goals 3, 9, and 17, as well as the goals of the G20 initiative.
摘要：
1987年，Won发明了固相多孔微球(MS)，在许多相互连接的空隙中储存生物活性化合物。球形颗粒（5-300μm），MS,可能会形成更小的球体簇，产生许多好处。目前的调查集中在凝胶包裹的配方，这可以适合皮肤使用。首先,使用准乳液(w/o/w)溶剂蒸发来制备5-氟尿嘧啶(5FU)MS颗粒。对最终产品进行了表征（SEM显示多孔结构，FTIR和DSC显示药物与辅料的相容性,和凝胶制剂是剪切稀化的），并使用8倍方法进一步扩大规模。此外，实施CCD（中央复合设计）以获得优化的结果。优化条件后，包括聚合物(600毫克，乙基纤维素(EC),eudragitRS100(ERS))，搅拌速度(1197rpm),和表面活性剂浓度(2%w/v)，我们取得了以下结果：最佳收率(63%)，平均粒径(152微米)，药物包封率（76%），和累积药物释放(8h内74.24%)。这些发现对工业应用很有希望，与联合国可持续发展目标3、9和17中概述的目标以及G20倡议的目标一致。
